search
Back to results

Tuberculosis Preventive Therapy Among Latent Tuberculosis Infection in HIV-infected Individuals

Primary Purpose

HIV-infected Participants With Latent TB Infection in High TB Burden Country

Status
Recruiting
Phase
Phase 3
Locations
Thailand
Study Type
Interventional
Intervention
Isoniazid/Rifapentine daily (4 weeks) plus pyridoxine (vitamin B6)
Isoniazid/Rifapentine 12-weekly plus pyridoxine (vitamin B6)
Sponsored by
The HIV Netherlands Australia Thailand Research Collaboration
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for HIV-infected Participants With Latent TB Infection in High TB Burden Country focused on measuring people living with HIV (PLHIV)

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Documented HIV-1 infection by standard HIV test or plasma HIV-1 RNA viral load and received ART within 12 months. Participants received ART more than 12 months would be allowed if CD4 cell counts is less than 350 cells/mm3
  2. 18 years and older
  3. Evidence of latent TB infection, either by TST ≥5 mm or positive interferon gamma release assay (IGRA) or history of close contact with active pulmonary TB* within 3 months prior entry visit or residing in a high TB burden area** NOTE * close contact is referred to person living/sharing in the same room with active pulmonary TB participants for > 4 hours/day

    ** high TB burden areas are defined as areas with an estimated or reported TB prevalence of 100 to 300/100,000, according to the WHO. Thailand is included in high TB burden areas.

  4. Laboratory values obtained within 30 days prior to entry

    • Absolute neutrophil count (ANC) >750 cells/mm3
    • Hemoglobin >7.4 g/dL
    • Platelet count >50,000/mm3
    • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) <3x upper limit of normal (ULN)
    • Total bilirubin <2.5 X ULN
  5. Chest radiograph or chest computed tomography (CT) scan without evidence of active tuberculosis, unless one has been performed within 90 days prior to entry.
  6. Female participants who are participating in sexual activity that could lead to pregnancy must agree to use one reliable non-hormonal form of contraceptive (i.e., condoms, IUD, diaphragm) during RPT treatment and contraception should be remain to 6 weeks post RPT NOTE Female participants who are not of reproductive potential or whose male partner(s) have undergone successful vasectomy with documented azoospermia or have documented azoospermia are eligible without requiring the use of contraceptives. Participant-reported history is acceptable documentation of menopause, hysterectomy, or bilateral oophorectomy or bilateral tubal ligation.
  7. All participants must agree not to participate in a conception process (e.g., active attempt to become pregnant or to impregnate, donate sperm, in vitro fertilization) while receiving RPT and for 6 weeks after stopping this drug.
  8. Body weight > 40 kg
  9. Ability and willingness of participant to provide informed consent

Exclusion Criteria:

  1. Treatment for active or latent TB (pulmonary or extrapulmonary) within 2 years prior to study entry or presence of any confirmed or probable active TB at screening.
  2. History of Isoniazid (INH) or Rifampicin (RIF)/Rifabutin (RFB) resistant TB at any time prior to study entry or known exposure to INH or RIF/RFB resistant TB (e.g., household member of a person with MDR or XDR TB) at any time prior to study entry.
  3. Treatment for >14 consecutive days with a rifamycin or >30 consecutive days with INH at any time during the 2 years prior to enrollment.
  4. Current or planned use of protease inhibitor-based ART.
  5. Currently on a salvage ART regimen, defined as a regimen started due to confirmed HIV virologic failure on a prior ART regimen or due to known HIV drug resistance.
  6. History of liver cirrhosis at any time prior to study entry.
  7. Evidence of acute hepatitis, such as abdominal pain, jaundice, dark urine, and/or light stools within 90 days prior to entry.
  8. Diagnosis of porphyria at any time prior to study entry.
  9. Peripheral neuropathy ≥Grade 2 according to the Division of AIDS (DAIDS) Toxicity Table, within 90 days prior to study entry.
  10. Known allergy/sensitivity or any hypersensitivity to components of study drug(s) or their formulation.
  11. Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
  12. Acute or serious illness requiring systemic treatment and/or hospitalization within 30 days prior to entry.
  13. Pregnancy or breastfeeding

Sites / Locations

  • Klang Hospital
  • Bhumibol Adulyadej Hospital
  • HIV-NAT, Thai Red Cross AIDS Research CentreRecruiting
  • King Chulalongkorn Memorial Hospital
  • Police General Hospital
  • Taksin Hospital
  • the Public Health Centre 28 Krung thon buri
  • Sanpatong Hospital
  • Chiangrai Prachanukroh Hospital
  • Queen Savang Vadhana Memorial Hospital
  • Srinagarind Hospital
  • Maharat Nakhon Ratchasima Hospital
  • Pranangklao Hospital
  • Buddhachinnaraj Hospital
  • Sisaket Hospital
  • Hatyai Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

1HP

3HP

Arm Description

4-week daily regimen of weight-based RPT and INH, plus pyridoxine (vitamin B6)

12-weekly INH/RPT regimen, plus pyridoxine (vitamin B6)

Outcomes

Primary Outcome Measures

efficacy in preventing active TB (proportion of participants that do not have active TB by the end of the study)
proportion of participants that do not have active TB by the end of the study
safety of the regimens (proportion of participants that do not have any side effects throughout the study period)
proportion of participants that do not have any side effects throughout the study period
tolerability to the regimens (proportion of participants that can complete the treatment course)
proportion of participants that can complete the treatment course
prevalence of drug resistance of MTB
proportion of participants with drug resistance to MTB

Secondary Outcome Measures

severity of the condition
proportion of participants that have side effects of grade more than or equal to 3 signs
presence of symptoms
proportion of participants that have symptoms during the study period
level of CBC
assess the level of CBC
level of ALT
assess the level of ALT
level of AST
assess the level of AST
level of total bilirubin
assess the level of total bilirubin
level of ALK
assess the level of ALK
level of creatinine
assess the level of creatinine
death
time from randomization to death from any cause (TB and non TB events)
when TB culture becomes positive
how much time does it take to have positive TB culture
when TB is confirmed by clinical examination
how much time does it take to have TB diagnosed via clinical examination
adherence to LTBI treatment
proportion of pills missed during treatment period based on self report
consistency of taking LTBI treatment
proportion of pills missed during treatment period based on clinical assessment
treatment discontinuation
proportion of participants with permanent LTBI treatment discontinuation due to all causes
discontinuation of study due to adverse drug reactions
Proportion of participants that have discontinued the study because of adverse drug reactions
CD4 count
CD4 count at baseline
CD4 count to confirmed or probable TB
CD4 count at time from randomization to culture-confirmed or probable TB
time it takes for TB to be confirmed by IGRA
how much time does it take to confirm TB diagnosis via IGRA
TST result at baseline
TST result at day 0

Full Information

First Posted
December 19, 2018
Last Updated
March 22, 2022
Sponsor
The HIV Netherlands Australia Thailand Research Collaboration
Collaborators
King Chulalongkorn Memorial Hospital, Police General Hospital, Pranangklao Hospital, Taksin Hospital, Bhumibol Adulyadej Hospital, Klang Hospital, Chiang Rai Prachanukroh Hospital, Sanpatong Hospital, Queen Sawang Vadhana Memorial Hospital, Buddhachinnaraj Hospital, Maharat Nakhon Ratchasima Hospital, Hatyai Hospital, Srinagarind Hospital, Khon Kaen University, Sisaket Hospital, The Public Health Centre 28 Krung thon buri
search

1. Study Identification

Unique Protocol Identification Number
NCT03785106
Brief Title
Tuberculosis Preventive Therapy Among Latent Tuberculosis Infection in HIV-infected Individuals
Official Title
Implementation for Tuberculosis Preventive Therapy Among Latent Tuberculosis Infection in HIV-infected Individuals Using Novel Regimen of Isoniazid/Rifapentine Daily (4 Weeks) Compared to Isoniazid/Rifapentine Weekly (12 Weeks)
Study Type
Interventional

2. Study Status

Record Verification Date
March 2022
Overall Recruitment Status
Recruiting
Study Start Date
August 15, 2019 (Actual)
Primary Completion Date
March 2023 (Anticipated)
Study Completion Date
March 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
The HIV Netherlands Australia Thailand Research Collaboration
Collaborators
King Chulalongkorn Memorial Hospital, Police General Hospital, Pranangklao Hospital, Taksin Hospital, Bhumibol Adulyadej Hospital, Klang Hospital, Chiang Rai Prachanukroh Hospital, Sanpatong Hospital, Queen Sawang Vadhana Memorial Hospital, Buddhachinnaraj Hospital, Maharat Nakhon Ratchasima Hospital, Hatyai Hospital, Srinagarind Hospital, Khon Kaen University, Sisaket Hospital, The Public Health Centre 28 Krung thon buri

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The investigators want to know if ultra-short, effective treatment for latent tuberculosis (TB) infection (LTBI) could dramatically reduce the global incidence of active TB or not. The investigators hypothesize that short-course (4-week) daily isoniazid/rifapentine (INH/RPT) (1HP) is not inferior to standard -course (12 weeks) INH/RPT weekly regimen (3HP) for the prevention of TB in human immunodeficiency virus (HIV)-infected individuals.
Detailed Description
This study is a multicenter, randomized, open-label, phase III clinical trial comparing a 4-week daily INH/RPT regimen (1HP) to a 12-weekly INH/RPT (3HP) for the treatment of LTBI in HIV-infected participants without evidence of active TB. The primary objective will be efficacy of active TB prevention. The study will also assess safety and tolerability of the regimens, adherence to the treatments, and patterns of antibiotic resistance among Mycobacterium tuberculosis (MTB) isolates in participants who fail on these prophylactic regimens. Under this study, there is one substudy entitled, "Pharmacokinetic study of rifapentine, dolutegravir, and tenofovir alafenamide in HIV-infected individual with latent tubersulosis infection". There will be a subgroup of patients who will participate in this pharmacokinetic study of rifapentine and dolutegravir (DTG) / tenofovir alafenamide (TAF). Randomization is based on cluster of differentiation 4 (CD4) categories : < 200, 200-350, > 500 cells/mm3 and VL <50 or >50 copies/ml.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV-infected Participants With Latent TB Infection in High TB Burden Country
Keywords
people living with HIV (PLHIV)

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
This study is a multicenter, randomized, open-label, phase III clinical trial comparing a 4-week daily INH/RPT regimen (1HP) to a 12-weekly INH/RPT (3HP) for the treatment of LTBI in HIV-infected participants without evidence of active TB.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
2500 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
1HP
Arm Type
Experimental
Arm Description
4-week daily regimen of weight-based RPT and INH, plus pyridoxine (vitamin B6)
Arm Title
3HP
Arm Type
Active Comparator
Arm Description
12-weekly INH/RPT regimen, plus pyridoxine (vitamin B6)
Intervention Type
Drug
Intervention Name(s)
Isoniazid/Rifapentine daily (4 weeks) plus pyridoxine (vitamin B6)
Intervention Description
Isoniazid/Rifapentine daily (4 weeks) plus pyridoxine (vitamin B6)
Intervention Type
Drug
Intervention Name(s)
Isoniazid/Rifapentine 12-weekly plus pyridoxine (vitamin B6)
Intervention Description
Isoniazid/Rifapentine 12-weekly plus pyridoxine (vitamin B6)
Primary Outcome Measure Information:
Title
efficacy in preventing active TB (proportion of participants that do not have active TB by the end of the study)
Description
proportion of participants that do not have active TB by the end of the study
Time Frame
3 years
Title
safety of the regimens (proportion of participants that do not have any side effects throughout the study period)
Description
proportion of participants that do not have any side effects throughout the study period
Time Frame
3 years
Title
tolerability to the regimens (proportion of participants that can complete the treatment course)
Description
proportion of participants that can complete the treatment course
Time Frame
3 years
Title
prevalence of drug resistance of MTB
Description
proportion of participants with drug resistance to MTB
Time Frame
3 years
Secondary Outcome Measure Information:
Title
severity of the condition
Description
proportion of participants that have side effects of grade more than or equal to 3 signs
Time Frame
3 years
Title
presence of symptoms
Description
proportion of participants that have symptoms during the study period
Time Frame
3 years
Title
level of CBC
Description
assess the level of CBC
Time Frame
3 years
Title
level of ALT
Description
assess the level of ALT
Time Frame
3 years
Title
level of AST
Description
assess the level of AST
Time Frame
3 years
Title
level of total bilirubin
Description
assess the level of total bilirubin
Time Frame
3 years
Title
level of ALK
Description
assess the level of ALK
Time Frame
3 years
Title
level of creatinine
Description
assess the level of creatinine
Time Frame
3 years
Title
death
Description
time from randomization to death from any cause (TB and non TB events)
Time Frame
3 years
Title
when TB culture becomes positive
Description
how much time does it take to have positive TB culture
Time Frame
3 years
Title
when TB is confirmed by clinical examination
Description
how much time does it take to have TB diagnosed via clinical examination
Time Frame
3 years
Title
adherence to LTBI treatment
Description
proportion of pills missed during treatment period based on self report
Time Frame
3 years
Title
consistency of taking LTBI treatment
Description
proportion of pills missed during treatment period based on clinical assessment
Time Frame
3 years
Title
treatment discontinuation
Description
proportion of participants with permanent LTBI treatment discontinuation due to all causes
Time Frame
3 years
Title
discontinuation of study due to adverse drug reactions
Description
Proportion of participants that have discontinued the study because of adverse drug reactions
Time Frame
3 years
Title
CD4 count
Description
CD4 count at baseline
Time Frame
3 years
Title
CD4 count to confirmed or probable TB
Description
CD4 count at time from randomization to culture-confirmed or probable TB
Time Frame
3 years
Title
time it takes for TB to be confirmed by IGRA
Description
how much time does it take to confirm TB diagnosis via IGRA
Time Frame
3 years
Title
TST result at baseline
Description
TST result at day 0
Time Frame
day 0

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Documented HIV-1 infection by standard HIV test or plasma HIV-1 RNA viral load and received ART within 12 months. Participants received ART more than 12 months would be allowed if CD4 cell counts is less than 350 cells/mm3 18 years and older Evidence of latent TB infection, either by TST ≥5 mm or positive interferon gamma release assay (IGRA) or history of close contact with active pulmonary TB* within 3 months prior entry visit or residing in a high TB burden area** NOTE * close contact is referred to person living/sharing in the same room with active pulmonary TB participants for > 4 hours/day ** high TB burden areas are defined as areas with an estimated or reported TB prevalence of 100 to 300/100,000, according to the WHO. Thailand is included in high TB burden areas. Laboratory values obtained within 30 days prior to entry Absolute neutrophil count (ANC) >750 cells/mm3 Hemoglobin >7.4 g/dL Platelet count >50,000/mm3 Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) <3x upper limit of normal (ULN) Total bilirubin <2.5 X ULN Chest radiograph or chest computed tomography (CT) scan without evidence of active tuberculosis, unless one has been performed within 90 days prior to entry. Female participants who are participating in sexual activity that could lead to pregnancy must agree to use one reliable non-hormonal form of contraceptive (i.e., condoms, IUD, diaphragm) during RPT treatment and contraception should be remain to 6 weeks post RPT NOTE Female participants who are not of reproductive potential or whose male partner(s) have undergone successful vasectomy with documented azoospermia or have documented azoospermia are eligible without requiring the use of contraceptives. Participant-reported history is acceptable documentation of menopause, hysterectomy, or bilateral oophorectomy or bilateral tubal ligation. All participants must agree not to participate in a conception process (e.g., active attempt to become pregnant or to impregnate, donate sperm, in vitro fertilization) while receiving RPT and for 6 weeks after stopping this drug. Body weight > 40 kg Ability and willingness of participant to provide informed consent Exclusion Criteria: Treatment for active or latent TB (pulmonary or extrapulmonary) within 2 years prior to study entry or presence of any confirmed or probable active TB at screening. History of Isoniazid (INH) or Rifampicin (RIF)/Rifabutin (RFB) resistant TB at any time prior to study entry or known exposure to INH or RIF/RFB resistant TB (e.g., household member of a person with MDR or XDR TB) at any time prior to study entry. Treatment for >14 consecutive days with a rifamycin or >30 consecutive days with INH at any time during the 2 years prior to enrollment. Current or planned use of protease inhibitor-based ART. Currently on a salvage ART regimen, defined as a regimen started due to confirmed HIV virologic failure on a prior ART regimen or due to known HIV drug resistance. History of liver cirrhosis at any time prior to study entry. Evidence of acute hepatitis, such as abdominal pain, jaundice, dark urine, and/or light stools within 90 days prior to entry. Diagnosis of porphyria at any time prior to study entry. Peripheral neuropathy ≥Grade 2 according to the Division of AIDS (DAIDS) Toxicity Table, within 90 days prior to study entry. Known allergy/sensitivity or any hypersensitivity to components of study drug(s) or their formulation. Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements. Acute or serious illness requiring systemic treatment and/or hospitalization within 30 days prior to entry. Pregnancy or breastfeeding
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Anchalee Avihingsanon, MD, PhD
Phone
026523040
Email
anchaleea2009@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
June Ohata, BS
Phone
026523040
Email
juneohata4@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anchalee Avihingsanon, MD, PhD
Organizational Affiliation
HIV-NAT, Thai Red Cross - AIDS Research Centre
Official's Role
Principal Investigator
Facility Information:
Facility Name
Klang Hospital
City
Bangkok
ZIP/Postal Code
10100
Country
Thailand
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Praniti Danpornprasert, MD
Phone
66897702021
Email
praniti_d@hotmail.com
First Name & Middle Initial & Last Name & Degree
Praniti Danpornprasert, MD
Facility Name
Bhumibol Adulyadej Hospital
City
Bangkok
ZIP/Postal Code
10220
Country
Thailand
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Chris Fujitnirun, MD
Phone
66834477602
Email
chris_nirun@hotmail.com
First Name & Middle Initial & Last Name & Degree
Chris Fujitnirun, MD
Facility Name
HIV-NAT, Thai Red Cross AIDS Research Centre
City
Bangkok
ZIP/Postal Code
10330
Country
Thailand
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anchalee Avihingsanon, MD, PhD
Phone
662 6523040
Email
anchaleea2009@gmail.com
First Name & Middle Initial & Last Name & Degree
June Ohata, BS
Phone
026523040
Ext
147
Email
juneohata4@gmail.com
Facility Name
King Chulalongkorn Memorial Hospital
City
Bangkok
ZIP/Postal Code
10330
Country
Thailand
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anchalee Avihingsanon, MD, PhD
Phone
66868128889
Email
anchaleea2009@gmail.com
First Name & Middle Initial & Last Name & Degree
Anchalee Avihingsanon, MD, PhD
Facility Name
Police General Hospital
City
Bangkok
ZIP/Postal Code
10330
Country
Thailand
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jirayu Visuthranukul, MD
Phone
6622076000
Email
nutjv@yahoo.com
First Name & Middle Initial & Last Name & Degree
Jirayu Visuthranukul, MD
Facility Name
Taksin Hospital
City
Bangkok
ZIP/Postal Code
10600
Country
Thailand
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Supunnee Jirajariyavej, MD
Phone
66813744264
Email
jsupunee@yahoo.com
First Name & Middle Initial & Last Name & Degree
Supunnee Jirajariyavej, MD
Facility Name
the Public Health Centre 28 Krung thon buri
City
Bangkok
ZIP/Postal Code
10600
Country
Thailand
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Thitisant Palakawong, MD
Phone
6628608210
Email
thitisant@gmail.com
First Name & Middle Initial & Last Name & Degree
Thitisant Palakawong, MD
Facility Name
Sanpatong Hospital
City
Chiang Mai
ZIP/Postal Code
50120
Country
Thailand
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Virat Klinbuayaem, MD
Phone
6653311404
Email
kggvirat@hotmail.com
First Name & Middle Initial & Last Name & Degree
Virat Klinbuayaem, MD
Facility Name
Chiangrai Prachanukroh Hospital
City
Chiang Rai
ZIP/Postal Code
57000
Country
Thailand
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Worarat Imsanguan, MD
Phone
66815568918
Email
minkworat@gmail.com
First Name & Middle Initial & Last Name & Degree
Worarat Imsanguan, MD
Facility Name
Queen Savang Vadhana Memorial Hospital
City
Chon Buri
ZIP/Postal Code
20110
Country
Thailand
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Palakorn Panarat, MD
Phone
66824401199
Email
panarat_3rd@hotmail.com
First Name & Middle Initial & Last Name & Degree
Palakorn Panarat, MD
Facility Name
Srinagarind Hospital
City
Khon Kaen
ZIP/Postal Code
40002
Country
Thailand
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
MD
Phone
66815925907
Email
ploencha@kku.ac.th
First Name & Middle Initial & Last Name & Degree
Ploenchan Chetchotisakd, MD
Facility Name
Maharat Nakhon Ratchasima Hospital
City
Nakhon Ratchasima
ZIP/Postal Code
30000
Country
Thailand
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sirichai Wiwatrojanagul, MD
Phone
66825321321
Email
md.sirichai@gmail.com
First Name & Middle Initial & Last Name & Degree
Sirichai Wiwatrojanagul, MD
Facility Name
Pranangklao Hospital
City
Nonthaburi
ZIP/Postal Code
11000
Country
Thailand
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sripetcharat Mekviwattanawong, MD
Phone
66818705700
Email
sripetcharat@gmail.com
First Name & Middle Initial & Last Name & Degree
Sripetcharat Mekviwattanawong, MD
Facility Name
Buddhachinnaraj Hospital
City
Phitsanulok
ZIP/Postal Code
65000
Country
Thailand
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Porntip Treebupachatsakul, MD
Phone
66915349221
Email
pornpitt@gmail.com
First Name & Middle Initial & Last Name & Degree
Porntip Treebupachatsakul, MD
Facility Name
Sisaket Hospital
City
Sisaket
ZIP/Postal Code
33000
Country
Thailand
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Natcha Saetiew, MD
Phone
66815937739
Email
snatcha39@gmail.com
First Name & Middle Initial & Last Name & Degree
Natcha Saetiew, MD
Facility Name
Hatyai Hospital
City
Songkhla
ZIP/Postal Code
90110
Country
Thailand
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Preudtipong Noopetch, MD
Phone
66815925907
Email
jasommhai@hotmail.com
First Name & Middle Initial & Last Name & Degree
Preudtipong Noopetch, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Tuberculosis Preventive Therapy Among Latent Tuberculosis Infection in HIV-infected Individuals

We'll reach out to this number within 24 hrs